Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 29790787)

  • 1. Colorectal Liver Metastases: A Pathologist's Guide to Creating an Informative Report and Improving Patient Care.
    Moreno Prats M; Sasatomi E; Stevenson HL
    Arch Pathol Lab Med; 2019 Feb; 143(2):251-257. PubMed ID: 29790787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy-induced Sinusoidal Injury (CSI) score: a novel histologic assessment of chemotherapy-related hepatic sinusoidal injury in patients with colorectal liver metastasis.
    Stevenson HL; Prats MM; Sasatomi E
    BMC Cancer; 2017 Jan; 17(1):35. PubMed ID: 28061766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathological factors and prognosis of resected liver metastases of colorectal carcinoma: implications and proposal for a pathological reporting protocol.
    Fonseca GM; Herman P; Faraj SF; Kruger JAP; Coelho FF; Jeismann VB; Cecconello I; Alves VAF; Pawlik TM; de Mello ES
    Histopathology; 2018 Feb; 72(3):377-390. PubMed ID: 28858385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of postoperative oxaliplatin- or irinotecan-based chemotherapy after curative resection of synchronous liver metastases from colorectal cancer.
    Hsu HC; Chou WC; Shen WC; Wu CE; Chen JS; Liau CT; Lin YC; Yang TS
    Anticancer Res; 2013 Aug; 33(8):3317-25. PubMed ID: 23898098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973).
    Goéré D; Pignon JP; Gelli M; Elias D; Benhaim L; Deschamps F; Caramella C; Boige V; Ducreux M; de Baere T; Malka D
    BMC Cancer; 2018 Aug; 18(1):787. PubMed ID: 30081865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
    Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM
    Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review.
    Richardson AJ; Laurence JM; Lam VW
    J Vasc Interv Radiol; 2013 Aug; 24(8):1209-17. PubMed ID: 23885916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe liver dysfunction and safe use of 5-fluorouracil leucovorin and oxaliplatin in one patient with metastatic colorectal carcinoma.
    Tural D; Akar E; Öztürk MA; Yıldız Ö; Turna H; Serdengeçti S
    J Cancer Res Ther; 2014; 10(3):745-8. PubMed ID: 25313774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure.
    Boige V; Malka D; Elias D; Castaing M; De Baere T; Goere D; Dromain C; Pocard M; Ducreux M
    Ann Surg Oncol; 2008 Jan; 15(1):219-26. PubMed ID: 17896145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histological liver injury and surgical outcome after FOLFOX followed by a hepatectomy for colorectal liver metastases in Japanese patients.
    Komori H; Beppu T; Baba Y; Horino K; Imsung C; Masuda T; Hayashi H; Okabe H; Ootao R; Watanabe M; Takamori H; Iyama K; Baba H
    Int J Clin Oncol; 2010 Jun; 15(3):263-70. PubMed ID: 20238233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proposal for novel histological findings of colorectal liver metastases with preoperative chemotherapy.
    Ishida K; Uesugi N; Hasegawa Y; Sugimoto R; Takahara T; Otsuka K; Nitta H; Kawasaki T; Wakabayashi G; Sugai T
    Pathol Int; 2015 Jul; 65(7):367-73. PubMed ID: 25940915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
    Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T
    J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-institutional phase II study on the feasibility of liver resection following preoperative mFOLFOX6 therapy for resectable liver metastases from colorectal cancers.
    Nagayama S; Hasegawa S; Hida K; Kawada K; Hatano E; Nakamura K; Seo S; Taura K; Yasuchika K; Matsuo T; Zaima M; Kanazawa A; Terajima H; Tada M; Adachi Y; Nishitai R; Manaka D; Yoshimura T; Doi K; Horimatsu T; Mitsuyoshi A; Yoshimura K; Niimi M; Matsumoto S; Sakai Y; Uemoto S
    Int J Clin Oncol; 2017 Apr; 22(2):316-323. PubMed ID: 27752787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of preoperative chemotherapy in patients with resectable colorectal liver metastases.
    Benoist S; Nordlinger B
    Ann Surg Oncol; 2009 Sep; 16(9):2385-90. PubMed ID: 19554377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basic research supported developments of chemotherapy in nonresectable isolated colorectal liver metastases to a protocol of hepatic artery infusion using mitoxantrone, 5-FU + folinic acid and mitomycin C.
    Link KH; Kornmann M; Leder G; Pillasch AF; Sunelaitis E; Schatz M; Pressmar J; Beger HG
    Gan To Kagaku Ryoho; 1999 Feb; 26(3):269-81. PubMed ID: 10065089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).
    Carrato A; Abad A; Massuti B; Grávalos C; Escudero P; Longo-Muñoz F; Manzano JL; Gómez A; Safont MJ; Gallego J; García-Paredes B; Pericay C; Dueñas R; Rivera F; Losa F; Valladares-Ayerbes M; González E; Aranda E;
    Eur J Cancer; 2017 Aug; 81():191-202. PubMed ID: 28633089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOLFOX enables high resectability and excellent prognosis for initially unresectable colorectal liver metastases.
    Beppu T; Hayashi N; Masuda T; Komori H; Horino K; Hayashi H; Okabe H; Baba Y; Kinoshita K; Akira C; Watanebe M; Takamori H; Baba H
    Anticancer Res; 2010 Mar; 30(3):1015-20. PubMed ID: 20393029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxaliplatin-induced liver injury mimicking metastatic tumor on images: a case report.
    Uchino K; Fujisawa M; Watanabe T; Endo Y; Nobuhisa T; Matsumoto Y; Kai K; Sato S; Notohara K; Matsukawa A
    Jpn J Clin Oncol; 2013 Oct; 43(10):1034-8. PubMed ID: 23958518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases.
    Klinger M; Eipeldauer S; Hacker S; Herberger B; Tamandl D; Dorfmeister M; Koelblinger C; Gruenberger B; Gruenberger T
    Eur J Surg Oncol; 2009 May; 35(5):515-20. PubMed ID: 19200687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.